WASHINGTON, DC – House Oversight and Government Reform Committee Chairman Trey Gowdy released the following statement after the Committee held a roundtable discussion to consider policy proposals pertaining to the Office of National Drug Control Policy (ONDCP) reauthorization.
“The opioid epidemic is growing rapidly and lives are at stake. It is imperative our nation maintain a strong, coordinated effort across the federal government to combat drug abuse. Today the Committee held a roundtable discussion with officials from ONDCP to discuss reauthorization. As we consider the discussion draft for ONDCP’s reauthorization, we welcome feedback from members of the public. The Committee also looks forward to holding a hearing on ONDCP next week.”
Today, the Committee released a discussion draft of legislation to reauthorize the Office of National Drug Control Policy (ONDCP) and implement recommendations included in the President’s Commission on Combating Drug Addiction and the Opioid Crisis.
The Committee welcomes feedback from members of the public as we make changes to the discussion draft. Comments, concerns, and suggestions may be submitted here.
- Next week, the Committee will hold an ONDCP reauthorization hearing.
- On April 11, 2018, the Subcommittee on Healthcare, Benefits, and Administrative Rules held a hearing to examine local responses and resources to curtail the opioid crisis.
- In March 2018, Committee staff held a roundtable discussion at a newly designated High Intensity Drug Trafficking Areas Program (HIDTA) district.
- In March 2018, Committee staff traveled to China to investigate the trafficking of illicit fentanyl through the U.S. Postal Service.
- On November 28, 2017, the Committee held a field hearing at Johns Hopkins Hospital in Baltimore to discuss the findings and recommendations from the President’s Commission on Combating Drug Addiction and the Opioid Crisis.
- On July 26, 2017, the Committee held a hearing to examine options for reauthorizing ONDCP and to discuss ONDCP’s effort to coordinate drug control policy and spending across the federal government.